Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesalazine + pantoprazole
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Rectal, Intravenous
01
Overview
Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory drug primarily used to treat mild to moderate ulcerative colitis and maintain remission. It acts mainly topically in the colon by inhibiting prostaglandin and leukotriene synthesis, reducing leukocyte migration, and scavenging free radicals[6]. Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+, K+-ATPase enzyme on gastric parietal cells[5]. The combination of mesalazine and pantoprazole has been studied for use in ulcerative colitis patients who excrete intact Asacol (a brand of mesalazine) tablets in their feces. Co-administration increases gastric pH, improving the release and absorption of mesalazine in the proximal gastrointestinal tract, thereby enhancing symptom management for these patients[1][3].
- Brand names
- AsacolProtonix
- Other names
- mesalamine + pantoprazole5-aminosalicylic acid + pantoprazole
02
Targets
5-lipoxygenase and related leukotriene synthesis enzymesATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on mesalazine + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesalazine + pantoprazole.